Market Potential Target hospitals and surgery centers seeking cost reduction and efficiency gains in enteral access procedures should be prioritized, as PUMA-G enables bedside gastrostomy tube insertion by non-surgical providers, potentially expanding addressable market and adoption in health systems focused on value-based care.

Strategic Partnerships Leverage collaboration with medtech accelerators and manufacturing partners such as LaunchPort to scale production of magnetic balloon catheters, accelerating regulatory-ready devices and expanding manufacturing capacity for broader geographic rollout.

Regulatory Readiness Capitalize on the streamlined FDA pathway observed for PUMA-G by highlighting fast-track opportunities to purchasing committees and risk-averse procurement teams, using the near-term regulatory clarity as a selling point for hospital capital budgets.

Clinical Evangelists Engage pediatric and adult gastroenterology and critical care leaders who can champion PUMA-G adoption, supported by clinical validation in anatomy studies and potential pediatric device grants to unlock expandability into pediatric units.

International Expansion Pursue Europe and other regions where CE marking enables targeted launches, aligning with distributors and regional KOLs to accelerate market entry and capitalize on existing goodwill from prior CE and Medtech Innovator recognitions.